Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872819 · ClinicalTrials.gov registry record · NA
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01872819 is a NA study that has completed, run by University of Washington. The registered enrollment target is 16 participants.
The verdict
NCT01872819, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to try to identify drugs that may be effective in killing leukemia cells for those patients who will not be cured with conventional chemotherapy. This assay will test multiple drugs simultaneously against a patient's own donated blood sample. The goal is to use this laboratory assay to best match a drug to a patient's disease.
Interventions
- DRUG chemotherapy
- OTHER antitumor drug screening assay
- BIOLOGICAL biological therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-08-02 |
| Est. Completion | 2014-11-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01872819
The ClinicalTrials.gov registry entry for NCT01872819 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which chemotherapy is the first listed.
NCT01872819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01872819 about?
NCT01872819 is a clinical study titled "Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay". This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to try to identify drugs that may be effective in killing leukemia cells for those patients who will not be cured wi...
What is the current status of trial NCT01872819?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2013-08-02. Estimated completion is 2014-11-17.
What interventions are being tested in trial NCT01872819?
The interventions under investigation include: chemotherapy (DRUG), antitumor drug screening assay (OTHER), biological therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01872819?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.